

Online Supplementary Table S1: Study and sample characteristics

First author, year	Interventions	Pts. included (N)	Diagnosis	Age (y)	Female	Total wart / IEN area (mm ²)	No. of warts / IEN areas	Duration of disease (m)	Previous treatment	HIV inclusion criteria	Mean CD 4+ cell count / stage of HIV
Gilson et al., 1999⁴	imiquimod 5% cream, 3x/w, up to 16w	65	external AGW of different location, clinical diagnosis	35 (SD 6.9)	3/65 (4.6%)	median 48.0 (range: 11-3612)	median 5 (range: 1-28)	median 12.0 (range: 0.3-173.9)	podo: 62%; cryo: 54%; electro: 28%	HIV sero-positive, CD4 T lymphocyte count $\geq 100 \times 10^6$ cells/L	median 270 (range: 13-1120) / HIV disease class: A: 30/65, B: 27/65, C: 8/65
	placebo cream (vehicle), 3x/w, up to 16w	35		33 (SD 8.3)	0/35 (0%)	median 60.5 (range: 10-2304)	median 5 (range: 1-14)	median 12.3 (range: 0.5-195.8)	podo: 46%; cryo: 54%; electro: 14%		median 273 (range: 89-710) / HIV disease class: A: 20/35, B: 12/35, C: 3/35
Fox et al., 2010³	imiquimod 5% cream, 3x/w, 16w	64	intraanal high grade IEN (AIN), histologically and high-res. anoscopy confirmed	41.8 (SD 6.6)	0% (excl.crit erion)	n.s.	n.s.	median 2.5 (range 2.0-7.5)	n.s.	HIV sero-positive on HAART for at least 3 months, CD4 cell count ≥ 100 cells/ μ l	median 329 (range: 258-514)
	placebo cream, 3x/w, 16w			42.3 (SD 7.4)				median 3 (range 2-14)			median 389 (range: 262-441)
Richel et al., 2013⁸	imiquimod 5% cream for intraanal or perianal application, 3x/w, 16w	57 (54)	intra- or perianal IEN (AIN, PAIN), confirmed by histology and high-resolution anoscopy	median 45 (IQR: 41-51)	0% (excl.crit erion)	n.s.	n.s.	n.s.	n.s.	HIV seropositive	535 (IQR: 395-695) / undetectable plasma HIV-RNA: 41/54 (67%)
	fluorouracil 2% cream, 2x/d perianal or 1x/d intraanal on 2d/w, 16w	50 (48)		median 47 (IQR: 40-54)							560 (IQR: 410-755) / undetectable plasma HIV-RNA: 39/48 (81%)
	electrocautery, monthly, 16w	49 (46)		median 47 (IQR: 42-55)							590 (IQR: 410-785) / undetectable plasma HIV-RNA: 38/45 (84%)
Viazis et al., 2007¹⁰	Argon plasma coagulation (ERBE APC300), every four weeks until complete clearance	7 HIV pos. (total group: 25)	intraanal warts, clinical diagnosis	n.r. (total group: 30.4 (SD 12.4))	n.r. (total group: 3/25 (12%))	n.s.	n.s.	n.s.	no previous treatment (inclusion criterion)	HIV seropositive	n.s.
	Argon plasma coagulation (ERBE APC300), every four weeks, + imiquimod 5% cream, 3x/w until complete clearance	6 HIV pos. (total group: 24)		n.r. (total group: 32.3 (SD 11.5))	n.r. (total group: 4/24 (16.7%))						

First author, year	Interventions	Pts. included (N)	Diagnosis	Age (y)	Female	Total wart / IEN area (mm ²)	No. of warts / IEN areas	Duration of disease (m)	Previous treatment	HIV inclusion criteria	Mean CD 4+ cell count / stage of HIV
Matteelli et al., 2001⁵	cidofovir 1% cream, 1x/d, 5x/w, 2w	6	external AGW of different location, clinical diagnosis	33.8	3/6 (50%)	n.s.	n.s.	n.s.	5/6	HIV seropositive, free of other HIV-related opportunistic infections or neoplasms	408/mm ³ / HIV disease class A: 5, B: 1, C: 0; HIV RNA (copies/ml): undetectable: 2, <10.000: 2, >10.000: 2
	placebo cream (vehicle), 1x/d, 5x/w, 2w	6		31.8	3/6 (50%)				4/6		136/mm ³ / HIV disease class A: 3, B: 2, C: 1; HIV RNA (copies/ml): undetectable: 1, <10.000: 4, >10.000: 1
Orlando et al., 2002⁶	cidofovir 1% gel, 1x/d, 5x/w, up to 6w	26	external AGW of different location, clinical diagnosis	33.4 (range: 24-41)	21/74 (28.4%)	mean lesion score: 76.6 (range: 5-292) [sum of size, number and location]	n.s.	n.s.	n.s.	HIV seropositive	264,9 x 10 ⁶ /l (range: 25-839) / HIV stage: III: 30/74, IVC2: 19/74, IVC1 or IVD: 25/74; HIV RNA detectable in 47/74 pts., mean viral load: 34,576 copies/ml
	electrocautery	29									
	electrocautery followed by cidofovir 1% gel, 1x/d, 5x/w, up to 2w	19									
Fleshner et al., 1994¹¹	IFN alpha-n3, 0.5 Mio IU, injected into the anoderm at each quadrant of the anal canal, immediately after surgical excision and fulguration of anal condylomata	13 HIV seropositive (total group: 25)	intraanal warts (+ other anogenital locations), clinical diagnosis	n.r. (total group: 35.8 (SD 2.4))	0%	n.r. (total group: percentage of anoderm: <10%: 2/25, 10-50%: 7/25, >50%: 16/25)	n.s.	n.r. (total group: 11.8 (SD 3.5))	n.r. (total group: Podo: 3/25, Surgery: 13/25, None: 9/25)	HIV seropositive (subgroup within the study sample)	344 (SD 57), range: 30-800
	Placebo, injected into the anoderm at each quadrant of the anal canal, immediately after surgical excision and fulguration of anal condylomata	7 HIV seropositive (total group: 18)		n.r. (total group: 32.6 (SD 1.7))							
Douglas et al., 1990²	IFN-alpha2b 1.5x10 ⁶ IU intralesional followed by topical podophyllin 25% solution 1x/w, 3w	6 HIV pos. (total group: 53)	external AGW of different location, clinical diagnosis	n.r. (total group: 29.4, SE 1.4)	n.r. (total group: 16/49 (32.7%))	n.r. (total group: 31.2mm ²)	n.r. (total group: 11.6, SE 2.2)	n.r. (total group: 2.5 years, SE 0.4)	n.r. (total group: 42/49)	HIV seropositive (subgroup within the study sample)	n.s.
	podophyllin 25% solution 1x/w, 3w	7 HIV pos. (total group: 56)		n.r. (total group: 28.4, SE 1.1)	n.r. (total group: 18/48 (37.5%))						

First author, year	Interventions	Pts. included (N)	Diagnosis	Age (y)	Female	Total wart / IEN area (mm ²)	No. of warts / IEN areas	Duration of disease (m)	Previous treatment	HIV inclusion criteria	Mean CD 4+ cell count / stage of HIV	
Brockmeyer et al., 2006¹	Electrosurgical ablation (warts >5mm) followed by 80µg peg. IFN-alpha 2b s.c., 1x/w, 24w	12	external, intraanal and vaginal AGW, clinical diagnosis, laboratory confirmation	38.2 (range 24 to 58 years)	1/12 (8.3%)	n.s.	n.s.	43.1 (range 1-92)	all had previous treatments: all had electrocautery, 7 had at least 2 different treatments	HIV seropositive, no active opportunistic infection within 12m prior to study entry	412.8 (range: 120-743) / HIV disease stage: A2: 3/12, B3: 2/12, C3: 7/12	
	Electrosurgical ablation of warts >5mm followed by no treatment	10		41.3 (range 30 to 62 years)	1/10 (10%)			37.1 (range 12-96)			392.9 (range: 126-826) / HIV disease stage: A2: 1/10, B2: 1/10, B3: 2/10, C2: 2/10, C3: 4/10	
Semprini et al., 1994⁹	IFN alpha-2b, 3 Mio IU i.m., every second day up to total of 45 Mio IU	9 HIV pos. (total group: 17)	"HPV genital lesions", clinical and histological assessment	n.s.	17/17 (100%)	inclusion criterion: lesions > 1cm ² at three non-contiguous sites	n.s.	n.s.	n.s.	HIV seropositive (subgroup within the study sample)	367/mm ³ (SD 138) / HIV stage: II: 9/17, III: 8/17	
	IFN beta 3 Mio IU i.m., every second day up to total of 45 Mio IU	8 HIV pos. (total group: 17)										
Palefsky et al., 2006⁷	100 µg SGN-00101 (fusion protein: HPV16 E7 with M. bovis heat shock protein 65) at baseline, week 4 and week 8 in alternating thighs	5	intraanal high grade intraepithelial lesion (AIN), histologically proven and confirmed with high-resolution anoscopy and cytology	47.5	2/15 (13%)	4x AIN °3 1x AIN °2	n.s.	n.s.	n.s.	HIV-positive on a stable HAART regimen ≥4w before study entry; HIV VL ≤500 copies/ml at enrollment; CD4 cell count ≥200/ml	711 cells/µl / median HIV VL (copies/ml): 75	
	500 µg SGN-00101 at baseline, week 4 and week 8 in alternating thighs	5									4x AIN °3 1x AIN °2	802 cells/µl / median HIV VL (copies/ml): 75
	1000 µg SGN-00101 at baseline, week 4 and week 8 in alternating thighs	5									3x AIN °3 2x AIN °2	585 cells/µl; median HIV VL (copies/ml): 75

Abbreviations: AGW, anogenital warts; AIN, anal intraepithelial neoplasia; d, days; IEN, intraepithelial neoplasia; IFN, interferon; IQR, inter quartile range; IU, international units; m, months; pts, participants; SD, standard deviation; SE, standard error; w, weeks; y, year